Skip to main content
All lobbying filings

Arentfox Schiff LLP

Arentfox Schiff LLP filed a Q3 report for Pharvaris Pharmaceuticals, Inc. (FKA Pharvaris, Inc.) on October 19, 2026, reporting $40,000 in lobbying income.

Lobbying for Pharvaris Pharmaceuticals, Inc. (FKA Pharvaris, Inc.) · Late-stage biopharmaceutical company

As filed: ARENTFOX SCHIFF LLP for PHARVARIS PHARMACEUTICALS, INC. (FKA PHARVARIS, INC.).

All filings by Arentfox Schiff LLP · Everything Pharvaris Pharmaceuticals, Inc. (FKA Pharvaris, Inc.) has reported

 Filing · LD-2 quarterly report Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 19, 2026
Income
$40,000
What the client paid this registrant for the period.
Client based in
Massachusetts

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Pharmacy

Advocacy of policies, legislation and regulation pertaining to pharmaceutical manufacturing, focusing on orphan drug production. H.R.5509 - Safe Step Act, generally

Medicare/Medicaid

Advocacy of policies, legislation and coverage of new pharmaceuticals in the orphan drug space.

 Bills named in this filing 1

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem